A systematic review of the antipsychotic properties of cannabidiol in humans

@article{Iseger2015ASR,
  title={A systematic review of the antipsychotic properties of cannabidiol in humans},
  author={Tabitha A Iseger and Matthijs G. Bossong},
  journal={Schizophrenia Research},
  year={2015},
  volume={162},
  pages={153-161}
}
Despite extensive study over the past decades, available treatments for schizophrenia are only modestly effective and cause serious metabolic and neurological side effects. Therefore, there is an urgent need for novel therapeutic targets for the treatment of schizophrenia. A highly promising new pharmacological target in the context of schizophrenia is the endocannabinoid system. Modulation of this system by the main psychoactive component in cannabis, Δ9-tetrahydrocannabinol (THC), induces… Expand
Could cannabidiol be used as an alternative to antipsychotics?
  • M. Fakhoury
  • Psychology, Medicine
  • Journal of psychiatric research
  • 2016
TLDR
CBD, a non-psychoactive component of cannabis, shows great promise for the treatment of psychosis, and is associated with fewer extrapyramidal side effects than conventional antipsychotic drugs. Expand
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders
TLDR
Preliminary clinical trials support the efficacy of CBD as an anxiolytic, antipsychotic, and antidepressant, and more importantly, a positive risk-benefit profile, and support the development of large-scale studies to further evaluate CBD as a potential new drug for the treatment of these psychiatric disorders. Expand
The Impact of Cannabidiol on Human Brain Function: A Systematic Review
TLDR
Neuroimaging studies have shown that acute CBD induces significant alterations in brain activity and connectivity patterns during resting state and performance of cognitive tasks in both healthy volunteers and patients with a psychiatric disorder. Expand
The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
TLDR
CBD, either as monotherapy or added to regular antipsychotic medication, improved symptoms in patients with schizophrenia, with particularly promising effects in the early stages of illness. Expand
Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
TLDR
Available evidence suggests that CBD may attenuate both psychotic-like symptoms induced by THC in healthy volunteers and positive symptoms in individuals with schizophrenia, and preliminary data on the efficacy of CBD for cannabis use disorders show mixed findings. Expand
Cannabinoids and Schizophrenia: Risks and Therapeutic Potential
TLDR
CBD may have therapeutic potential for the treatment of psychosis following cannabis use, as well as schizophrenia, possibly with better tolerability than current antipsychotic treatments, and CBD may also have anti-inflammatory and neuroprotective properties. Expand
Prospects for the Use of Cannabinoids in Psychiatric Disorders
TLDR
The prospects of using the psychoactive effects of cannabinoids in treating mental and psychiatric disorders are discussed, however, this evidence is weak for some clinical conditions and well-designed randomized controlled trials are currently lacking. Expand
Human Laboratory Studies on Cannabinoids and Psychosis
TLDR
Interactions between the endocannabinoid, gamma-aminobutyric acid, and glutamate systems and their individual and interactive effects on neural oscillations provide a plausible mechanism underlying the psychotomimetic effects of cannabinoids. Expand
Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol
TLDR
Future cannabis-related policy decisions should include consideration of scientific findings, including the individual and interactive effects of CBD and THC, as well as other cannabinoid molecules currently being evaluated for medicinal purposes, separately and in combination. Expand
Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms
TLDR
This review presents a comprehensive critical overview of the current literature related to the antidepressant effects of CBD, with focus at the possible mechanisms. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 91 REFERENCES
A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.
Δ(9)-tetrahydrocannabinol (Δ(9)-THC) is the main compound of the Cannabis Sativa responsible for most of the effects of the plant. Another major constituent is cannabidiol (CBD), formerly regarded toExpand
Cannabis and psychiatric disorders: it is not only addiction
TLDR
It became apparent that cannabis use is not only frequent in patients suffering from BD, but that it also induces manic symptoms in this group and cannabinoid compounds could display a new class of medication, as suggested by the fatty acid amino hydrolase inhibitor URB597 in animal models. Expand
Cannabidiol monotherapy for treatment-resistant schizophrenia
TLDR
The preliminary data suggest that CBD monotherapy may not be effective for TRS, and patients with treatment-resistant schizophrenia should be switched to olanzapine for over 15 days. Expand
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
TLDR
It is suggested that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia. Expand
Cannabidiol as a potential treatment for psychosis
TLDR
Evidence from several research domains suggests that CBD shows potential for antipsychotic treatment, and an overview of currently available animal, human experimental, imaging, epidemiological and clinical studies that investigated the antipsychotics properties of CBD is provided. Expand
Role of the endocannabinoid system in brain functions relevant for schizophrenia: An overview of human challenge studies with cannabis or ∆9-tetrahydrocannabinol (THC)
Accumulating evidence suggests involvement of the endocannabinoid system in the pathophysiology of schizophrenia, which signifies a potential application for this system in the treatment of thisExpand
Acute and non-acute effects of cannabis on human memory function: a critical review of neuroimaging studies.
TLDR
Results of neuroimaging studies that investigated acute and non-acute effects of cannabis on human learning and memory function, both in adults and in adolescents show that cannabis use is associated with a pattern of increased activity and a higher level of deactivation in different memory-related areas. Expand
Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction
TLDR
Delta-9-tetrahydrocannabinol is associated with transient exacerbation in core psychotic and cognitive deficits in schizophrenia, and this data do not provide a reason to explain why schizophrenia patients use or misuse cannabis. Expand
Cannabidiol for the treatment of psychosis in Parkinson’s disease
TLDR
Preliminary data suggest that CBD may be effective, safe and well tolerated for the treatment of the psychosis in PD. Expand
Cerebrospinal Anandamide Levels are Elevated in Acute Schizophrenia and are Inversely Correlated with Psychotic Symptoms
TLDR
The results suggest that anandamide elevation in acute paranoid schizophrenia may reflect a compensatory adaptation to the disease state, and the endocannabinoids are a family of bioactive lipids that activate CB1 cannabinoid receptors in the brain and exert intense emotional and cognitive effects. Expand
...
1
2
3
4
5
...